Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822617 | 0.79 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL1521576 | 0.79 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL20457638 | 0.79 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL15694522 | 0.79 | CA1 (0.56) | CA1CA2CA9 | |
| SCHEMBL22758811 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL26189646 | 0.73 | CA1 (0.35) | CA1CA2CA9MGAMGAA | |
| SCHEMBL7213237 | 0.73 | — | — | |
| SCHEMBL17944612 | 0.72 | CA1 (0.36) | CA1CA2CA9MGAMGAA | |
| SCHEMBL14414659 | 0.71 | CA2 (0.43) | CA1CA2CA9MGAMGAA | |
| SCHEMBL10083642 | 0.71 | CA2 (0.43) | CA1CA2CA9MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155652-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | CA1 4872/4885CA2 4796/4885CA9 4617/4885 |
| US-11692005-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | CA1 4872/4885CA2 4796/4885CA9 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.